Intercept Pharmaceuticals (NASDAQ:ICPT) Downgraded by Credit Suisse Group
Intercept Pharmaceuticals (NASDAQ:ICPT) was downgraded by investment analysts at Credit Suisse Group from an “outperform” rating to a “neutral” rating in a research report issued on Monday, Marketbeat.com reports. They presently have a $59.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $137.00. Credit Suisse Group’s price target indicates a potential upside of 23.15% from the stock’s current price.
Other research analysts have also issued research reports about the company. Wedbush reiterated a “buy” rating and issued a $257.00 target price on shares of Intercept Pharmaceuticals in a research report on Thursday, May 14th. Stifel Nicolaus decreased their target price on Intercept Pharmaceuticals from $100.00 to $51.00 and set a “hold” rating for the company in a research report on Monday. Canaccord Genuity lowered Intercept Pharmaceuticals from a “buy” rating to a “hold” rating and set a $58.00 price objective for the company. in a research report on Monday. Raymond James lowered Intercept Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Monday. Finally, Citigroup lowered Intercept Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $110.00 price objective for the company. in a research report on Tuesday, May 12th. Eighteen equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $81.48.
Shares of NASDAQ ICPT opened at $47.91 on Monday. Intercept Pharmaceuticals has a fifty-two week low of $44.50 and a fifty-two week high of $125.00. The business has a 50 day moving average price of $78.84 and a two-hundred day moving average price of $88.09. The company has a quick ratio of 4.19, a current ratio of 4.19 and a debt-to-equity ratio of 10.32. The firm has a market cap of $2.55 billion, a PE ratio of -4.47 and a beta of 1.82.
In other Intercept Pharmaceuticals news, Director Paolo Fundaro sold 595,578 shares of Intercept Pharmaceuticals stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $84.60, for a total transaction of $50,385,898.80. Following the sale, the director now owns 19,433 shares of the company’s stock, valued at approximately $1,644,031.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 595,817 shares of company stock worth $50,405,516 in the last ninety days. 23.70% of the stock is owned by company insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Public Employees Retirement Association of Colorado raised its stake in shares of Intercept Pharmaceuticals by 20.9% in the 1st quarter. Public Employees Retirement Association of Colorado now owns 4,290 shares of the biopharmaceutical company’s stock worth $270,000 after buying an additional 742 shares in the last quarter. Sarissa Capital Management LP raised its stake in shares of Intercept Pharmaceuticals by 34.3% in the 1st quarter. Sarissa Capital Management LP now owns 1,155,000 shares of the biopharmaceutical company’s stock worth $72,718,000 after buying an additional 295,000 shares in the last quarter. Twinbeech Capital LP bought a new stake in shares of Intercept Pharmaceuticals in the 1st quarter worth $928,000. Advisor Group Holdings Inc. bought a new stake in shares of Intercept Pharmaceuticals in the 1st quarter worth $4,732,000. Finally, Engineers Gate Manager LP bought a new stake in shares of Intercept Pharmaceuticals in the 1st quarter worth $1,467,000. 76.46% of the stock is currently owned by institutional investors.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Featured Article: What is Elliott Wave theory?
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.